Skip to main content
Article thumbnail
Location of Repository

Photofrin II as an efficient radiosensitizing agent in an experimental tumor

By Moshe Schaffer, Pamela Manuela Schaffer, L. Corti, G. Sotti, Alfons Hofstetter, G. Jori and Eckhart Dühmke


Background and Objective: The use of ionizing irradiation as radiation therapy (RT) for tumor treatment represents a well-established method. The use of photodynamic therapy (PDT), especially with Photofrin II, for tumor treatment is also known. Chemical modifiers enhancing the action of radiation therapy are well known and widely used in medicine. None of these compounds, however, is a selective radiosensitizer. Materials and Methods: Several series of animal experiments were performed, The highly differentiated human bladder cancer cell line RT4 was implanted subcutaneously in nude mice. The mice were injected 10 mg/kg Photofrin II and irradiated with 5 Gy. Results: Photofrin II has proved to be a chemical modifier of ionizing irradiation, enhancing the tumor doubling time (tumor growth) from 6.2 to 10.9 days in the control group with the use of irradiation and injection of porphyrin. Conclusion: Photofrin II shows a high activity as radiosensitizer and, in the future, can be used as a selective radiosensitizer for tumor treatment with ionizing radiation.

Topics: Medizin, ddc:610
Publisher: Ludwig-Maximilians-Universität München
Year: 2001
DOI identifier: 10.1159/000055130
OAI identifier:
Provided by: Open Access LMU

Suggested articles


  1. Beroukas K: Outcome of patients receiving photodynamic therapy for early esophageal cancer.
  2. (1996). Hofstädter F: The combined effects of high energy shock waves and ionising radiation on human bladder cancer cell line. Ultrasound Med Biol
  3. (1989). In vivo transport and pharmacokinetic behaviour of tumor photosensitizers: in Bock G, Harnett S (eds): Photosensitizing Compounds: Their Chemistry, Biology and Clinical Use. Ciba Foundation Symp 146.
  4. (1994). JG: Evidence for low-density lipoproteins receptor mediated uptake of benzoporphyrin derivative.
  5. (1997). Kligerman MM: Chemical modifiers of radiation;
  6. (1986). Martuza RL: The interaction of hematoporhyrin derivative, light, and ionizing radiation in a rat glioma model.
  7. (1978). Modification of radiosensitivity by porphyrins: Studies of tumors and other systems;
  8. (1987). PA: A new in vivo model to study invasion and metastasis of human bladder carcinoma. Cancer Res
  9. (1998). Peng Q: Photodynamic therapy.
  10. (1997). Photodynamic therapy for choroidal neurovascularization in a phase II study. Assoc Res Vision Ophthalmol
  11. (1997). Ricchelli F: Sr(IV)-methoxythylene-glycolnaphthalocyanine: Synthesis and pharmacokinetic and photosensitizing properties in different tumor models.
  12. Schwartz S: Modification of radiosensitivity by porphyrins II, transplanted rhabdomyosarcoma in mice.
  13. (1990). The chemical composition of Photofrin.
  14. TJ: Basic principles of photodynamic therapy.
  15. Tumour photosensitizers: Approaches to enhance the efficiency and selectivity of photodynamic therapy.
  16. (1996). Z: A comparative study of tissue distribution and photodynamic therapy selectivity of chlorin c6, Photofrin II and ALA- induced protoporphyrin IX in a carcinoma model.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.